Effect of COX-1 and COX-2 inhibition on induction and maintenance of carrageenan-evoked thermal hyperalgesia in rats

被引:0
|
作者
Dirig, DM
Isakson, PC
Yaksh, TL
机构
[1] Univ Calif San Diego, Dept Anesthesiol, La Jolla, CA 92093 USA
[2] Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA
关键词
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Intrathecal administration of nonsteroidal anti-inflammatory drugs in the rat blocks the thermal hyperalgesia induced by tissue injury, which suggests a role for spinal cyclooxygenase (COX) products in this facilitated state. Two isozymes of the COX enzyme have been reported, COX-1 and COX-2, but the agents thus far examined are not isozyme selective. We examined the effects of intrathecally (i.t.) or systemically (i.p.) administered S(+)-ibuprofen (a nonselective COX inhibitor) or 1-[(4-methysulfonyl)phenyl]-3-tri-fluoromethyl-5-(4-fluorophenyl)pyrazole (SC58125; a COX-2 selective inhibitor) on carrageenan-induced thermal hyperalgesia (reduced hindpaw-withdrawal latency). The following observations were made: 1) Thermal hyperalgesia otherwise observed during the first 170 min was blocked in a dose-dependent manner by S(+)-ibuprofen or SC58125 administered i.t. or i.p. before carrageenan treatment. 2) Intraperitoneal, but not i.t., administration of either inhibitor after the establishment of hyperalgesia (170 min after carrageenan injection) reversed thermal hyperalgesia in a dose-dependent manner. Thus, the initial component of thermal hyperalgesia after tissue injury was blocked by systemic or spinal administration of both COX inhibitors, whereas established hyperalgesia was reversed only by systemic inhibitors. This study demonstrates that at least spinal COX-2, if not both COX-1 and COX-2, are necessary for the initiation of thermal hyperalgesia, whereas nonspinal sources of prostanoids (synthesized by COX-2 and perhaps also COX-1) are important for the maintenance of thermal hyperalgesia associated with tissue injury and inflammation.
引用
收藏
页码:1031 / 1038
页数:8
相关论文
共 50 条
  • [21] Selective inhibition of monocyte COX-2 vs platelet COX-1 in humans
    McAdam, BF
    Kapoor, S
    CatellaLawson, F
    Fitzerald, GA
    CIRCULATION, 1997, 96 (08) : 3117 - 3117
  • [22] Pharmacologic Inhibition of COX-1 and COX-2 in Influenza A Viral Infection in Mice
    Carey, Michelle A.
    Bradbury, J. Alyce
    Rebolloso, Yvette D.
    Graves, Joan P.
    Zeldin, Darryl C.
    Germolec, Dori R.
    PLOS ONE, 2010, 5 (07):
  • [23] COX-1, COX-2 and dual inhibition in a model of colorectal adenocarcinoma.
    Brown, JR
    Seed, MP
    Freemantle, CN
    Colville-Nash, PR
    Kwong, E
    Somerville, KW
    Evans, JF
    Willis, D
    Willoughby, DA
    JOURNAL OF PATHOLOGY, 1999, 187 : 10A - 10A
  • [24] Effect of dexamethasone on gastric mucosal integrity in rats treated with a COX-1 or a COX-2 inhibitor
    Gretzer, B
    Schuligoi, R
    Peskar, BM
    GASTROENTEROLOGY, 2001, 120 (05) : A151 - A151
  • [25] COX-1 and COX-2 products in the gut: therapeutic impact of COX-2 inhibitors
    Whittle, BJR
    GUT, 2000, 47 (03) : 320 - 325
  • [26] Roles of COX-1 and COX-2 in gastrointestinal pathophysiology
    Choitsu Sakamoto
    Journal of Gastroenterology, 1998, 33 : 618 - 624
  • [27] THE DEVELOPMENT OF COX-1 AND COX-2 INHIBITORS: A REVIEW
    Vishwakarma, Rahul Kumar
    Negi, D. S.
    INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES AND RESEARCH, 2020, 11 (08): : 3544 - 3555
  • [28] COX-1 and COX-2 expression in osteoid osteomas
    Mungo, DV
    Zhang, XP
    O'Keefe, RJ
    Rosier, RN
    Puzas, JE
    Schwarz, EM
    JOURNAL OF ORTHOPAEDIC RESEARCH, 2002, 20 (01) : 159 - 162
  • [29] Roles of COX-1 and COX-2 in gastrointestinal pathophysiology
    Sakamoto, C
    JOURNAL OF GASTROENTEROLOGY, 1998, 33 (05) : 618 - 624
  • [30] Meranzin: A new COX-1/COX-2 inhibitory
    Renimel, I
    Fanton, L.
    Andre, P.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2009, 129 : S96 - S96